Bms-986278 clinical trial
WebApr 10, 2024 · Bristol-Myers Squibb: ClinicalTrials.gov Identifier: NCT05805904 Other Study ID Numbers: IM027-067 : First Posted: April 10, 2024 Key Record Dates: Last Update Posted: April 10, 2024 Last Verified: March 2024 WebJul 13, 2024 · The Autotaxin (ATX)-Lysophosphatidic Acid (LPA) Axis. Phospholipid growth factors (PLGFs) are a family of lipids with growth factor-like properties. Lysophosphatidic acid (LPA) is a member of the PLGF family that promotes a diverse range of physiological cellular functions by binding to specific G-protein-coupled receptors (LPAR 1–6), present ...
Bms-986278 clinical trial
Did you know?
WebSep 28, 2024 · Specific to PF-ILD, the LPA 1 antagonist, BMS-986278, has shown promise in preclinical and phase I studies (67, 68) and is currently in phase 2 clinical trials, with study arms for both IPF and PF ... WebO portal para as doenças raras e os medicamentos órfãos
WebMar 12, 2024 · December 3, 2024 updated by: Bristol-Myers Squibb A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the … WebBMS-986278, a second-generation LPA 1 antagonist, is currently in phase 2 development as a therapy for IPF and PF-ILD. Methods and analysis: This phase 2, randomised, … National Center for Biotechnology Information
WebMar 1, 2024 · BMS-986020, BMS-986234 and BMS-986278, are three lysophosphatidic acid receptor 1 (LPA1) antagonists that were or are being investigated for treatment of … WebBMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with Kbs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases. ... Clinical Trial: Molecular Weight: 445.51 Appearance: Solid Formula: C 22 H 31 N 5 O 5. CAS No. …
WebBristol Myers Squibb is committed to sustaining its strong leadership and legacy in the development of transformational therapeutics for treating patients with malignant and benign hematological conditions. • Our focus is on Multiple Myeloma, Lymphoma and CLL, MDS, AML, MPNs (e.g., myelofibrosis) and thalassemias
WebSep 28, 2024 · Maximum observed plasma concentration (Cmax) of BMS-986278 [ Time Frame: Up to 15 days ] ... For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. ... Bristol-Myers Squibb: ClinicalTrials.gov Identifier: NCT04567667 Other Study ID Numbers: hs2 colne valley mapWebBMS-986278 for Pulmonary Fibrosis Clinical Trial 2024 Power Apply to this Phase 2 clinical trial treating Pulmonary Fibrosis, Fibrosis. Get access to cutting edge treatment via BMS … hobbs occasion coatsWebMar 1, 2024 · Abstract. In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 6.2 μM) and inhibited BA canalicular efflux in human hepatocytes (68% … hs2 contract awardhs2 construction managerWebMar 1, 2024 · BMS-986234 and BMS-986278 are both potent LPA 1 antagonists that are structurally distinct from BMS-986020 (Cheng et al., 2024) (Fig. 1).BMS-986234 was discontinued prior to clinical development due to an unfavorable nonclinical pharmacokinetic profile (Cheng et al., 2024).BMS-986278 is currently being evaluated in … hs2 construction news birminghamWebMar 16, 2024 · The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety … hs2 contracts listWebMar 1, 2024 · In a Phase 2 clinical trial, BMS-986020, a lysophosphatidic acid receptor-1 (LPA 1 ) antagonist, produced hepatobiliary toxicity (increased ALT, AST, and ALP; cholecystitis) and increases in plasma bile acids (BA). ... (BMS-986234 and BMS-986278). BMS-986020 inhibited hepatic BA efflux transporters BSEP (IC 50 1.8 μM), MRP3 (IC 50 … hs2 contract type